Latest news with #Eylea
Bloomberg
6 days ago
- Business
- Bloomberg
Bayer Gets Boost From Older Drugs, Corn Seeds in Outlook Lift
Bayer AG benefited from surprisingly strong demand for its aging blockbuster eye and blood-thinning medicines in the second quarter, helping the German company raise its forecast for the year. Sales of the eye treatment Eylea came in at €862 million ($998 million) for the period, exceeding analyst estimates, while blood-thinner Xarelto added another €650 million despite facing new generic competition, according to a statement Wednesday that offered a fuller picture of the company's performance than last week's initial announcement.
Business Insider
04-08-2025
- Business
- Business Insider
Regeneron price target raised to $753 from $750 at Bernstein
Bernstein analyst William Pickering raised the firm's price target on Regeneron (REGN) to $753 from $750 and keeps an Outperform rating on the shares. The company reported a 'very strong' Q2 but also announced a new round of regulatory setbacks, the analyst tells investors in a research note. The firm says an FDA inspection at an ex-Catalent site has led to a second complete response letter for odronextemab and an expected delay in pending FDA decisions on Eylea. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Reuters
01-08-2025
- Business
- Reuters
Regeneron posts better-than-expected Q2 results, downplays tariff impact
Aug 1 (Reuters) - Regeneron (REGN.O), opens new tab topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on imports from the European Union. Under the U.S.-EU trade deal announced earlier this week, all branded medicines will be subject to a 15% broad tariff. As the company gains clarity on details of the agreement and other potential tariffs, CEO Leonard Schleifer said the 15% duties were not expected to have a material impact. Investors have set a high bar for Regeneron and French partner Sanofi's ( opens new tab Dupixent, one of the U.S. drugmaker's growth drivers. Sales of the anti-inflammatory drug came in at $4.34 billion, beating analysts' estimate of $4.14 billion, according to data compiled by LSEG. U.S. sales of its eye-disease drug Eylea, jointly developed with Bayer AG ( opens new tab, fell 25% to $1.15 billion, missing an estimate of $2.17 billion. The higher, 8-milligram dose of the drug brought in sales of $393 million. Shares of the drugmaker initially rose 5% but pared most gains after Regeneron said the U.S. Food and Drug Administration had declined to approve its blood cancer therapy, citing process-related issues at a fill-finish site in Bloomington, Indiana. The site, which is also used to manufacture high-dose Eylea, has caused a delay for three regulatory filings of the drug. Novo Nordisk ( opens new tab, which acquired the site from Catalent, is in touch with the regulator about these problems. Regeneron earned adjusted quarterly profit of $12.89 per share, compared with analysts' average expectation of $8.44 per share. Its total second-quarter revenue was $3.68 billion, above an expectation of $3.28 billion. The company is also among 17 drugmakers that have received a letter from President Donald Trump asking them to slash prescription drug prices in the United States to match overseas rates.
Yahoo
25-07-2025
- Business
- Yahoo
Regeneron Pharmaceuticals Earnings Preview: What to Expect
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $61.8 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The biotechnology company is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Friday, Aug. 1. Ahead of the event, analysts expect REGN to report a profit of $6.23 per share on a diluted basis, down 38.3% from $10.10 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For the full year, analysts expect REGN to report EPS of $28.27, down 26.8% from $38.62 in fiscal 2024. However, its EPS is expected to rise 9.3% year over year to $30.90 in fiscal 2026. REGN stock has significantly underperformed the S&P 500 Index's ($SPX) 17.3% gains over the past 52 weeks, with shares down 46.8% during this period. Similarly, it considerably underperformed the Health Care Select Sector SPDR Fund's (XLV) 9.4% dip over the same time frame. REGN is facing challenges due to declining sales of its key drug Eylea, amid increased competition from Roche Holding AG's (RHHBY) Vabysmo and potential biosimilars. The company's partnership with Sanofi (SNY) has also seen setbacks, including mixed results from late-stage studies on itepekimab. These factors have negatively impacted REGN's stock performance, and the company has a tough road ahead in diversifying its revenue streams and offsetting the decline in Eylea sales. On Apr. 29, REGN shares closed down by 6.9% after reporting its Q1 results. Its adjusted EPS of $8.22 fell short of Wall Street's expectations of $8.43. The company's revenue was $3 billion, falling short of Wall Street forecasts of $3.3 billion. Analysts' consensus opinion on REGN stock is reasonably bullish, with an overall 'Moderate Buy' rating. Out of 25 analysts covering the stock, 17 advise a 'Strong Buy' rating, one suggests a 'Moderate Buy,' six give a 'Hold,' and one recommends a 'Moderate Sell.' REGN's average analyst price target is $737.71, indicating a potential upside of 30.7% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Cision Canada
24-07-2025
- Business
- Cision Canada
DRI Healthcare to Host Second Quarter 2025 Earnings Call and Webcast on August 14, 2025
TORONTO, July 24, 2025 /CNW/ - DRI Healthcare Trust (TSX: (TSX: DHT.U) ("DRI Healthcare"), a global leader in providing financing to advance innovation in the life sciences industry, today announced that it will hold a conference call to discuss its second quarter 2025 financial results on Thursday, August 14, 2025, at 8:00 a.m. ET. The Trust will report its financial results on Wednesday, August 13, 2025, after market close. All interested parties may join the conference call by dialling 416-945-7677 or 1-888-699-1199 approximately 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins. To join the conference call without operator assistance, you may register and enter your phone number at to receive an instant automated callback. A question-and-answer session will follow management's prepared remarks, at which time the operator will provide instructions for qualified equity analysts to submit questions. A live webcast of the conference call, including a slide presentation, will be available at Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived on the Trust's website following the call date. About DRI Healthcare DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3.0 billion, acquiring more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol " and in U.S. dollars under the symbol "DHT.U". To learn more, visit or follow us on LinkedIn.
